Eisai Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo, founded in 1941. Eisai developed donepezil, marketed as Aricept, one of the most widely prescribed treatments for Alzheimer's disease symptoms following its approval in the late 1990s. More recently, Eisai co-developed lecanemab, marketed as Leqembi, with the American biotechnology company Biogen, minted in this same wave, an antibody treatment aimed at slowing the progression of early Alzheimer's disease rather than only treating its symptoms. Eisai maintains a particular research focus on neurology and oncology alongside its broader pharmaceutical portfolio.
Facts
Company Type
Company Type (category) Founded Year Connections
Operates In
Source Eisai (company) (Wikipedia)
In the Other Atlases
Located In
Also in Geography Atlas: where this subject is located.
Sources
1. Eisai (company) (Wikipedia)
Infobox: founded
December 6, 1941
Infobox: type
Public KK
Operates In: Pharmaceutical Industry, Infobox: industry
Pharmaceuticals
View the SourceReader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.